Active Not RecruitingNCT07172516

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Depression in bipolarity)

A short description of this study’s research objective has not yet been verified.

Medication studyAges 18–74Multiple countries

The study in practice

Understand this study

Who could participate?

This study is for people with bipolarity. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.

Listed locations: Tucson, United States · Little Rock, United States and 39 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 8, 2025

Recruitment status: Active Not Recruiting
Enrollment listed in the registry: 400
Sponsor: Xenon Pharmaceuticals Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Bulgaria, Germany, ...
Age range: From 18 Years to 74 Years
Official registry ID: NCT07172516
Official title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT07172516. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Not recruiting

Tucson, United States · Little Rock, United States · Rogers, United States

38 more locations

Bellflower, United States
Culver City, United States
Orange, United States
Riverside, United States
Walnut Creek, United States
Coral Gables, United States
Gainesville, United States
Jacksonville, United States
Miami, United States
Orlando, United States
Atlanta, United States
Decatur, United States
Stone Mountain, United States
Elgin, United States
Orland Park, United States
O'Fallon, United States
Las Vegas, United States
Cherry Hill, United States
Toms River, United States
Brooklyn, United States
Cedarhurst, United States
Staten Island, United States
Charlotte, United States
Allentown, United States
Memphis, United States
Atascocita, United States
Houston, United States
Wichita Falls, United States
Everett, United States
Kazanlak, Bulgaria
Lovech, Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Dresden, Germany
Münster, Germany
Madrid, Spain
Palma de Mallorca, Spain
Pontevedra, Spain

A listed location does not confirm current availability.

Study drug

About the molecule

When a study medicine is clearly identified, HopeStage adds a short explanation of what that molecule is and links back to reliable public sources.

Azetukalner

an experimental Kv7 potassium-channel opener

targets Kv7 potassium channels

Official source More context

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Xenon Pharmaceuticals Inc.

Does this study involve medication?

Yes. The study involves medication, including Azetukalner and Placebo.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me